the aid library

LIST OPTIONS

Filter

5828

Sort by:

Direction:

Download (913)

View PDF (1976)

Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective

World Health Organization (2012) C_WHO

1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization

Download (11823)

View PDF (2466)

Panduan Praktik Klinis (PPK) dan Clinical Pathway (CP) Penyakit Jantung dan Pembuluh Darah

Firdaus, I., A.U. Rahajoe, A. F. Yahya, et al., Indonesian Heart Association (2016) C1

Clinical Practice Guidelines and Clinical Pathway for Therapy and Management of Heart Disease and Blood Vessels in Indonesia

Download (3775)

View PDF (1694)

Pedoman Tatalaksana Hipertensi Pada Penyakit Kardiovaskular

Soenarta, A.A., Erwinanto, A.S.S. Mumpuni, et al., Indonesian Heart Association (2015) C1

Guidelines for Therapy and Management of Hypertension in Cardiovascular Disease in Indonesia

Download (86)

View PDF (150)

The Critical Role of the Staff Nurse in Antimicrobial Stewardship—Unrecognized, but Already There

Olans R. N. , R. D. Olans, A. DeMaria Jr Clinical Infectious Diseases (2016) C2

An essential participant in antimicrobial stewardship who has been unrecognized and underutilized is the“staff nurse.”Although the role of staff nurses has not formally been recognized in guidelines for implementing and operating antimicrobial stewardship programs (ASPs) or defined in the medica... more

Download (87)

View PDF (741)

Methicillin-ResistantStaphylococcus aureus(MRSA):Prevalence and Antimicrobial Sensitivity Pattern among Patients—A Multicenter Study in Asmara, Eritrea

Yohaness Garoy E., Y. Berhane Gebreab, O. Okoth Achila et al. Hindawi (2018) C2

Methicillin-resistant Staphylococcus aureus(MRSA) strainsor multidrug-resistant S.aureus, initially described in 1960s,emerged in the last decade as a cause of nosocomial infections responsible for rapidly progressive, potential fatal diseases including life-threatening pneumonia, necrotizing fascii... more

Download (116)

View PDF (148)

Statement on the Use of Ivermectin for COVID-19

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1

Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States. Currently... more

Download (54)

View PDF (829)

Investing in drug-resistant tuberculosis household contact management and preventive treatment

Hussain.H.; Malik, A. A. The Lancet (2022) CC

Preventing tuberculosis infection from progressing to tuberculosis disease is a crucial component of the goal to eliminate tuberculosis. When deciding on the use of tuberculosis preventive therapy among household contacts, policy makers regularly ask questions, such as whether tuberculosis preventiv... more

Download (136)

View PDF (166)

Covid-19 Test to Treat Guidelines
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t... more

Download (84)

View PDF (714)

Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership.

Bernhard, S.; Kaiser, M.; Burri, C.; Mäser, P. Diseases (2022) CC

After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge... more

Download (25)

View PDF (18)

2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines

Hitzeroth, J.; Mpe, M.; Klug, E. et al. The South African Medical Journal (2020) CC

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t... more

Download (36)

View PDF (24)

Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes

Park, J.J. Diabetes & Metabolism Journal (2021) CC

The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit... more

Download (11)

View PDF (9)

Limited access to CVD medicines in low-income and middle-income countries: poverty is at the heart of the matter

Agyemang, C.; van den Born, B. The Lancet Global Health (2018) CC

Non-communicable diseases (NCDs) pose a substantial threat to many health systems, especially in low-income and middle-income countries (LMICs) where they are already overstretched. In the past few decades, deaths from NCDs in LMICs have spiked, whereas numbers in high-income countries have stabilis... more

Download (24)

View PDF (23)

Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (March 2024)

World Health Organization WHO (2024) C_WHO

Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease. The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics. These include expanded and simplified treatment criteria for adults but now also for adolescents; expa... more

Download (20)

View PDF (15)

Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps

Blanco, I.; Diego, I.; Bueno, P. et al. (2019) CC2

Existing data on chronic obstructive pulmonary disease (COPD) prevalence are irregularly distributed around the world, and in many geographic regions data are scarce or even nonexistent. This fact hinders the implementation of adequate preventive and therapeutic interventions to reduce the high burd... more

Download (14)

View PDF (17)

COPD Foundation Educational Materials - EPOC 201: Más allá de lo básico

COPD Foundation COPD Foundation (2022) CC2

The document provides comprehensive guidance for people with COPD, covering treatment and medication management, oxygen therapy, mucus control, exercise, smoking cessation, nutrition, associated conditions, and strategies to prevent exacerbations. It emphasizes patient education, self-management, an... more

Download (24)

View PDF (17)

COPD Foundation Educational Materials - BPCO 201 - pour aller plus loin

COPD Foundation COPD Foundation (2022) CC2

The document provides practical guidance for individuals with COPD, covering topics such as medication management, oxygen therapy, mucus control, physical exercise, smoking cessation, nutrition, associated conditions, and how to prevent and manage exacerbations. It emphasizes the importance of patie... more

Download (21)

View PDF (13)

Summarizing the 2021 Updated GOLD Guidelines for COPD

Laisure, M.; Covill, N.; Ostroff, M.L.; Ostroff, J.L. U.S. Pharmacist (2021) CC2

Chronic obstructive pulmonary disease (COPD) is a complex disease that requires differential diagnosis and proper classification to identify appropriate therapy. Nonpharmacologic therapy and preventative measures should be utilized to prevent worsening of disease, symptoms, and complications. The Gl... more

Download (24)

View PDF (20)

Severe and Difficult Asthma: Diagnosis and Management—Challenges for a Low‐Resource Environment

Bush, A. Springer Link (2021) CC2

Severe and difficult asthma in a low- and middle-income country (LMIC) can relate to lack of availability of basic medications; potentially reversible factors such as poor adherence or comorbidities such as obesity inhibiting a good response to treatment; and (rarely) true severe, therapy-resistant ... more

Download (20)

View PDF (19)

Access to essential respiratory medications remains elusive in LMICs

Karmali, D.; Siddharthan, T. (2022) CC

Over 90% of the morbidity and mortality related to chronic obstructive pulmonary disease (COPD) and asthma occurs in low-income and middle-income countries (LMICs) due to well documented factors including decreased access to screening, trained health professionals, and therapies for disease manageme... more

Download (3)

View PDF (4)

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Guo, J.; Garratt, A.; Hill, A. Journal of Cystic Fibrosis (2022) CC

Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma... more

Covid-19 Test to Treat Guidelines recommended

Covid-19 Test to Treat Guidelines
recommended